Shares of Crispr Therapeutics were on the rise since Monday, shooting up almost 15% after the company announced that it and Vertex Pharmaceuticals have gained a key designation for a new gene-editing drug. It was on Tuesday that the IBD Relative Strength (RS) for Crispr rose to 93. The scale runs from 1-99 with 99 … Continue reading “Crispr Therapeutics Explodes 15% After New Blood Disease Drug Gets Fast-Track”
